American Gene Technologies (AGT) is a pioneering gene therapy biotech company focused on developing breakthrough treatments for HIV and other complex diseases. Leveraging a proprietary rapid gene delivery platform, AGT has created a pipeline of gene therapeutics that aim to teach the body to heal itself. The company serves patients with unmet medical needs, particularly those suffering from HIV, cancer, and rare genetic disorders. Operating in the biopharmaceutical market, AGT's business model revolves around the development and commercialization of intellectual property-protected gene therapies. Revenue is generated through clinical trials, licensing agreements, and potential future sales of approved therapies. AGT's innovative approach includes banking thousands of lentiviral vectors adaptable to various diseases, positioning it at the forefront of gene therapy advancements.

Keywords: gene therapy, HIV treatment, lentiviral vectors, immuno-oncology, rare diseases, biopharma, intellectual property, clinical trials, rapid gene delivery, biotech innovation.